Company profile: Newomics
1.1 - Company Overview
Company description
- Provider of integrative platforms for personalized healthcare, offering mass spectrometry and LC-MS solutions including DuoESI Source (dual ion source enhancing ionization for multiomics, compatible with leading mass spectrometers), MEA Chip (silicon LC column/ESI emitter/post-column inlet chip for improved sensitivity and robustness in proteomics), and M3 Emitter (silicon microfluidic flow-splitting emitter for enhanced ionization).
Products and services
- DuoESI Source: Dual-source ionization system that enhances ionization efficiency for multiomics analysis and is compatible with leading mass spectrometers
- M3 Emitter: Silicon microfluidic chip that splits LC flow into multiple streams for enhanced ionization, suitable for a wide range of LC-MS applications
- MEA Chip: Silicon-based chip integrating an LC column, ESI emitter, and post-column inlet for improved sensitivity and robustness in proteomics workflows
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Newomics
Aran Biomedical
HQ: Ireland
Website
- Description: Provider of design, development, and manufacturing of biomaterial-based medical implants, specializing in medical textiles, implant coatings, biomaterial frame encapsulation, and resorbable implantable solutions. Services span concept development, prototyping, and volume manufacturing, with knitting, braiding, weaving for implantable polymers, plus dip and spray coating using resorbable and non-resorbable materials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aran Biomedical company profile →
Intabio
HQ: United States
Website
- Description: Provider of real-time protein analytics and analytical solutions that transform biotherapeutic development and manufacturing by enabling early product quality characterization and delivering efficiency gains across all stages of biopharmaceutical development and manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intabio company profile →
Incept Biosystems
HQ: United States
Website
- Description: Provider of innovative microscale technologies that provide fertility specialists breakthrough capabilities to treat infertility, improving the in vitro manipulation, performance, and viability of high-value cells, with a mission to set the standard for next-generation clinical devices for Assisted Reproductive.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Incept Biosystems company profile →
3D Bio-Tissues
HQ: United Kingdom
Website
- Description: Provider of bio-equivalent tissues for clinical and cellular agriculture, including 3DBT corneas engineered to match human donor corneas, Tissue Templating Technology for structured, scalable tissues without animal components, City-Mix culture media supplement to enhance cell performance, and Etsyl, a lipopeptide that stimulates collagen production for cosmetic and pharmacological use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 3D Bio-Tissues company profile →
Cellink
HQ: Sweden
Website
- Description: Provider of bench-top bioprinters optimized for the bioprinting of human tissues.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellink company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Newomics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Newomics
2.2 - Growth funds investing in similar companies to Newomics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Newomics
4.2 - Public trading comparable groups for Newomics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →